Allon Therapeutics Inc

Entity type image
Type: Company
Name: Allon Therapeutics Inc
First reported May 02 2013 - Updated May 02 2013 - 1 reports

StemCells Inc: CEO Martin McGlynn Is Building A Blockbuster Company

ByBlackbirdAnalytics: In September 2012 I started sharing my biotech company trades on Seeking Alpha. Since then, I have recommended three names- Allon Therapeutics , Athersys and OncoGenex . Why just three companies in eight months? Because my ... [Published Healthcare Sector and Stocks Analysis from Seek ... - May 02 2013]
First reported Apr 29 2013 - Updated Apr 29 2013 - 2 reports

ALLON THERAPEUTICS INC.: Allon Therapeutics releases first quarter 2013 operating results

VANCOUVER, B.C. - Allon Therapeutics Inc.(TSX: NPC) today announced its unaudited operating results for the three months ended March 31, 2013.During the fourth quarter of 2012, Allon announced that its pivotal clinical trial evaluating its lead product ... [Published 4 Traders - Apr 29 2013]
First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Allon Therapeutics loses $1.07-million in Q1

Allon Therapeutics Inc. is releasing its unaudited operating results for the three months ended March 31, 2013.During the fourth quarter of 2012, Allon announced that its pivotal clinical trial evaluating its lead product candidate davunetide as a treatment ... [Published Stockwatch - Apr 29 2013]
First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Venture capital climate in Canada still chilly for biotechs

When Vancouver’s Punit Dhillon decided to start a biotechnology company, Oncosec, in 2011, he knew he would have to do it in the United States. Canada simply didn’t have the nurturing climate needed to launch the complicated cancer treatment he was developing. ... [Published Financial Post | Business » Entrepreneur - Apr 29 2013]
First reported Apr 23 2013 - Updated Apr 23 2013 - 1 reports

Cognitive Impairment - Pipeline Review, H1 2013

(M2 PRESSWIRE via COMTEX News Network) -- Research and Markets has announced the addition of the report to their offering. 'Cognitive Impairment - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides ... [Published PredictWallStreet - Apr 23 2013]
First reported Mar 27 2013 - Updated Mar 28 2013 - 1 reports

Allon loses $14.91-million in 2012

Allon Therapeutics Inc. has released its audited operating results for 2012.During the fourth quarter of 2012, Allon announced that its pivotal clinical trial evaluating its lead product candidate davunetide as a treatment for progressive supranuclear ... [Published Stockwatch - Mar 27 2013]
First reported Feb 05 2013 - Updated Feb 06 2013 - 1 reports
Toronto stock exchange
Toronto stock exchange

Allon has until May 30 to meet TSX obligations

Allon Therapeutics Inc.'s previously announced review has generated a number of different alternatives and opportunities that are being actively evaluated. The company is aggressively managing continuing operating expenses. This review process includes ... [Published Stockwatch - Feb 05 2013]
First reported Dec 24 2012 - Updated Dec 24 2012 - 1 reports

Allon Therapeutics' davunetide trial for PSP fails

Allon Therapeutics' clinical trial to assess davunetide efficacy in curing progressive supranuclear palsy (PSP) has failed to show efficacy. ... [Published PBR - News - Dec 24 2012]
First reported Dec 20 2012 - Updated Dec 20 2012 - 1 reports

CNS Drug Development Claims Another Victim

Tiny Allon Therapeutics had an ambitious plan to go after progressive supranuclear palsy , a kind of progressive brain deterioration, and thence (they hoped) to other neurodegenerative disorders. The lead compound was davunetide , an oligopeptide ... [Published In the Pipeline - Dec 20 2012]

Quotes

Gordon McCauley, Allon's president and chief executive officer, said: "The company is continuing to evaluate its strategic options going forward and believes that there are logical strategic options for the business. Assuming that one of these transactions completes, we believe the company will be able to meet its obligations; however, until that process is complete, we will continue to aggressively manage cash."
Allon loses $14.91-million in 2012 [Published Stockwatch - Mar 27 2013]

More Content

All (21) | News (11) | Reports (1) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (5)
sort by: Date | Relevance
New Market Study Published: Traumatic Brain Inj... [Published Live-PR.com - May 07 2013]
StemCells Inc: CEO Martin McGlynn Is Building A... [Published Healthcare Sector and Stocks Analysis from Seek ... - May 02 2013]
ALLON THERAPEUTICS INC.: Allon Therapeutics rel... [Published 4 Traders - Apr 29 2013]
Allon Therapeutics loses $1.07-million in Q1 [Published Stockwatch - Apr 29 2013]
Allon Therapeutics releases first quarter 2013 ... [Published Canada NewsWire - Apr 29 2013]
Venture capital climate in Canada still chilly ... [Published Financial Post | Business » Entrepreneur - Apr 29 2013]
Recently released market study: Traumatic Brain... [Published Live-PR.com - Apr 25 2013]
Cognitive Impairment - Pipeline Review, H1 2013 [Published PredictWallStreet - Apr 23 2013]
Schizophrenia - Pipeline Review, H1 2013: New r... [Published Live-PR.com - Apr 20 2013]
Research and Markets: Amyotrophic Lateral Scler... [Published Yahoo! Finance - Apr 12 2013]
Amyotrophic Lateral Sclerosis - Pipeline Review... [Published Individual.com - Apr 12 2013]
Allon loses $14.91-million in 2012 [Published Stockwatch - Mar 27 2013]
Allon has until May 30 to meet TSX obligations [Published Stockwatch - Feb 05 2013]
TSX Delisting Review - Allon Therapeutics Inc. ... [Published Financial Services - Feb 05 2013]
Allon Therapeutics' davunetide trial for PSP fails [Published PBR - News - Dec 24 2012]
CNS Drug Development Claims Another Victim [Published In the Pipeline - Dec 20 2012]
Allon announces PSP clinical trial results [Published PR Newswire: Health - Dec 18 2012]
The United States, New Zealand & Mexico Issue P... [Published PR Newswire: General Business - Dec 05 2012]
Allon selected as Top 10 partnering prospect by... [Published PR Newswire: Health - Nov 29 2012]
Monday Deal Review: November 26, 2012 [Published The Cross-Border Biotech Blog - Nov 26 2012]
Allon files preliminary shelf prospectus [Published PR Newswire: Health - Nov 22 2012]
1
In Focus
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Venture capital climate in Canada still chilly ... [Published Financial Post | Business » Entrepreneur - Apr 29 2013]
When Vancouver’s Punit Dhillon decided to start a biotechnology company, Oncosec, in 2011, he knew he would have to do it in the United States. Canada simply didn’t have the nurturing climate needed to launch the complicated cancer treatment he was developing. ...
Allon Therapeutics' davunetide trial for PSP fails [Published PBR - News - Dec 24 2012]
Allon Therapeutics' clinical trial to assess davunetide efficacy in curing progressive supranuclear palsy (PSP) has failed to show efficacy. ...
CNS Drug Development Claims Another Victim [Published In the Pipeline - Dec 20 2012]
Tiny Allon Therapeutics had an ambitious plan to go after progressive supranuclear palsy , a kind of progressive brain deterioration, and thence (they hoped) to other neurodegenerative disorders. The lead compound was davunetide , an oligopeptide ...
Monday Deal Review: November 26, 2012 [Published The Cross-Border Biotech Blog - Nov 26 2012]
Welcome to your Monday Biotech Deal Review for November 26, 2012. This past week saw Valeant continue their aggressive stock repurchase program. Valeant plans to repurchase up to $1.5 billion worth of its own stock, senior notes or debt. Further, we ...
1

Press Releases

sort by: Date | Relevance
TSX Delisting Review - Allon Therapeutics Inc. ... [Published Financial Services - Feb 05 2013]
Allon announces PSP clinical trial results [Published PR Newswire: Health - Dec 18 2012]
The United States, New Zealand & Mexico Issue P... [Published PR Newswire: General Business - Dec 05 2012]
Allon selected as Top 10 partnering prospect by... [Published PR Newswire: Health - Nov 29 2012]
Allon files preliminary shelf prospectus [Published PR Newswire: Health - Nov 22 2012]
1
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.